Methods and reagents are disclosed for preparing a liquid solution of a receptor. The methods comprise combining in a liquid medium the receptor, a chelating agent and a C2-C6 polyol. An amount of the chelating agent and the C2-C6 polyol is sufficient to achieve a stable and active receptor in the liquid solution, which is maintained at a temperature of about 2° C. to about 40° C. The compositions may be employed in assays for the determination of analytes that include receptor-binding analytes.

Methods and reagents are disclosed for preparing a liquid solution of a receptor. The methods comprise combining in a liquid medium the receptor, a chelating agent and a C2-C6 polyol. An amount of the chelating agent and the C2-C6 polyol is sufficient to achieve a stable and active receptor in the liquid solution, which is maintained at a temperature of about 2° C. to about 40° C. The compositions may be employed in assays for the determination of analytes that include receptor-binding analytes.

The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.

The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.

The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.

Disclosed herein are immunoassays for detecting an antibody in a biological sample from a subject and/or diagnosing an autoimmune disease in a subject. The disclosed immunoassays use a single, direct step to assess the level of antibody in a biological sample from the subject by simultaneously binding the antibody to a capture antigen (e.g. an unlabeled antigen bound to a solid support) and a labeled antigen not bound to the solid support.

Disclosed herein are immunoassays for detecting an antibody in a biological sample from a subject and/or diagnosing an autoimmune disease in a subject. The disclosed immunoassays use a single, direct step to assess the level of antibody in a biological sample from the subject by simultaneously binding the antibody to a capture antigen (e.g. an unlabeled antigen bound to a solid support) and a labeled antigen not bound to the solid support.

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human transthyretin (TTR). The anti-TTR antibodies or antigen-binding fragments thereof are useful, for example, in detecting TTR and in treating TTR amyloidosis in a subject.

A method and kit the simultaneous analysis of thyroid hormones (THs) and related metabolites in serum are disclosed. The method includes the extraction of THs and related metabolites, the derivatization of THs and related metabolites with 5-N-succinimidoxy-5-oxopentyl)triphenylphosphonium bromide (SPTPP), and the analysis of SPTPP derivatives using ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Free or total THs (T3 and T4) together with their related metabolites (MIT, DIT, T0, T1, rT1, 3,3′-T2, 3,5-T2, and rT3) can be determined simultaneously, rapidly, and accurately. This invention overcomes the limitation that the traditional method can only be used for the analysis of T3 and T4 with low specificity. The invention exhibits extremely high analytical sensitivity for all of the target analytes (femtogram level). Moreover, this invention also possesses numerous other advantages, such as simple sample pretreatment, accurate determination, low cost, high efficiency, effective separation, and small sample amounts.

A method and kit the simultaneous analysis of thyroid hormones (THs) and related metabolites in serum are disclosed. The method includes the extraction of THs and related metabolites, the derivatization of THs and related metabolites with 5-N-succinimidoxy-5-oxopentyl)triphenylphosphonium bromide (SPTPP), and the analysis of SPTPP derivatives using ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Free or total THs (T3 and T4) together with their related metabolites (MIT, DIT, T0, T1, rT1, 3,3′-T2, 3,5-T2, and rT3) can be determined simultaneously, rapidly, and accurately. This invention overcomes the limitation that the traditional method can only be used for the analysis of T3 and T4 with low specificity. The invention exhibits extremely high analytical sensitivity for all of the target analytes (femtogram level). Moreover, this invention also possesses numerous other advantages, such as simple sample pretreatment, accurate determination, low cost, high efficiency, effective separation, and small sample amounts.